Washington, D.C. (PRWEB) April 26, 2007
Eye on FDA, RX for Pharma Industry, Communications and Planning, a blog launched last year by Mark Senak, J.D., Senior Vice President at Fleishman-Hillard in Washington D.C., has launched a new podcast series in addition to regular postings on issues affecting the healthcare regulatory and policy environment.
Most recently, Mark Senak sat down with Andrew Jack, pharmaceutical correspondent for the Financial Times of London to look at the post-Vioxx era and the trends and parallels between the FDA and EMEA in terms of public perception, inter-agency influence and transparency. The interview with Andrew Jack is Mark's first major outing in the European region and poses some interesting questions for the pharmaceutical industry.
Mark has also interviewed a number of people recently in this ongoing Eye on FDA podcast series, including
o Julie Zawisza (Assistant Commissioner for Public Affairs at FDA),;
o Kip Piper (a former White House Budget Officer and author of The Piper Report),
o Adam Feuerstein (Senior Columnist at TheStreet.com).
Upcoming slated interviews include Linda Suydam, CEO of the Consumer Healthcare Products Association, Jeff Levi, Executive Director of the Trust for America's Health and former Health and Human Services Secretary Lewis Sullivan.
MARK SENAK and EYE ON FDA
'Eye on FDA' has a diverse 'readership', including national media, government officials, patient groups, law firms, stock analysts and pharmaceutical companies themselves. Mark Senak is the authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; issues and crisis management. Frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!